There are 2789 resources available
263P - Predicting bevacizumab efficacy in mTNBC
Presenter: Heba Bakri
Session: ePoster Display
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Presenter: Sarat Chandarlapaty
Session: ePoster Display
244P - Real-world first-line treatment patterns and outcomes in hormone-receptor positive advanced breast cancer patients: A multicenter, retrospective study
Presenter: Zhanhong Chen
Session: ePoster Display
246P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study
Presenter: Antonios Valachis
Session: ePoster Display
294P - Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
Presenter: Lorenza Palmero
Session: ePoster Display
295P - Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
Presenter: Lucia Bortot
Session: ePoster Display
296P - Recapitulation of organ-specific breast cancer metastasis using an engineered multi-tissue platform
Presenter: Alan Chramiec
Session: ePoster Display